Lightning Round: You've got the best with CrowdStrike, says Jim Cramer

Key Concepts

Investment Advice on Specific Stocks

Pfizer (PFE): Andrew in New York is holding Pfizer since 2005, reinvesting dividends, but his cost basis is now higher than the current value. Cramer advises to wait two more quarters to see the impact of the acquisition before deciding whether to hold or sell ("fish or cut bait"). He wants to give Doctor Boyle more time.
CrowdStrike (CRWD): Smitty in North Carolina is up 200% on CrowdStrike and considering selling to invest in a cybersecurity ETF. Cramer advises against this, stating CrowdStrike is the best in the sector (other than Palo Alto Networks). He recommends taking out the cost basis and letting the rest run, predicting the stock will reach $1,000.
Lowe's (LOW): Scott in New York bought Lowe's at $224, it went to $228, and has a price target of $300. Cramer advises to hold, citing Marvin Ellison's performance and the challenges of the current housing market (due to the Fed not cutting rates and low housing turnover). He states he won't quit on Marvin Ellison.

Investment Strategies

Reinvesting Dividends: The case of Pfizer highlights the risk that even with reinvested dividends, a stock's price can decline, resulting in a loss.
Taking Out Cost Basis: With CrowdStrike, Cramer suggests a strategy of taking out the initial investment (cost basis) and allowing the remaining shares to appreciate without the pressure of potential losses.
Concentrated vs. Diversified Investments: The discussion about CrowdStrike versus a cybersecurity ETF touches on the trade-off between focusing on a high-performing stock versus diversifying across multiple companies, including potentially mediocre ones.

Market Commentary

The Lightning Round segment is sponsored by Charles Schwab.
The upcoming segment will discuss whether the fear of a parabolic market is overblown and how portfolios can benefit.